Aranesp, Procrit Face New Headwind With Tumor-Specific Restrictions
Executive Summary
The sponsors of erythropoiesis-stimulating agents are hoping FDA will make its next round of label updates for the anemia therapies based on the totality of clinical data rather than clinical trials evaluating Amgen's Aranesp (epoetin alfa) and Johnson & Johnson's Procrit (darbepoetin alfa) in specific cancers
You may also be interested in...
FDA Panel Votes To Limit ESA Cancer Use To Metastatic Patients
Following the recommendations of its Oncologic Drugs Advisory Committee, FDA's next step in ensuring the safe use of erythropoiesis-stimulating agents will be to determine how best to narrow the approved indication for anemia treatment in the cancer setting
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.